What Is CJC-1295 with DAC?
CJC-1295 with DAC is a 30-amino-acid synthetic peptide analog of GHRH carrying a Drug Affinity Complex — a lysine-based linker that covalently binds to circulating serum albumin after injection. This albumin binding shields the peptide from enzymatic degradation and extends its half-life from the ~30-minute window of native GHRH to approximately 6–8 days.
Mechanism of Action
CJC-1295 DAC binds to and activates GHRH receptors on somatotroph cells in the anterior pituitary, triggering growth hormone synthesis and secretion. Because the DAC-modified peptide circulates for days rather than minutes, it produces a sustained elevation in GH levels rather than a sharp pulse — a pharmacokinetic profile fundamentally distinct from native GHRH and from the no-DAC version.
Research Applications
Studies have investigated CJC-1295 DAC for GH replacement, body composition optimization (lean mass gain, fat reduction), recovery from injury and training, and anti-aging protocols. Its once-weekly or twice-weekly dosing schedule makes it a practical subject for sustained GH secretagogue research compared to daily injections.
Comparison with No-DAC Version
The key distinction between CJC-1295 with DAC and without DAC (Modified GRF 1-29) is the pharmacokinetic profile. DAC produces steady, blunted GH elevation over days. No-DAC produces sharp, physiologically normal GH pulses that closely mimic the body's natural secretion pattern. Researchers select between them based on whether sustained baseline elevation or pulsatile mimicry is the research objective.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Comparative Pharmacokinetics: DAC vs Non-DAC Variants (2015)
Human | Crossover design | 30 days each arm - Long-term Effects on GH/IGF-1 Axis (2012)
Animal model | 6 months | Weekly dosing - Dose-Response Relationship of CJC-1295 DAC (2008)
Human | Multiple doses | 90 days | 48 subjects - Prolonged Growth Hormone Elevation with CJC-1295 DAC (2006)
Human | 30-60mcg/kg | Single injection | 12 subjects - The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Dominikowski A, Rękoś Z, Olejarz M, 2026, Front Endocrinol (Lausanne)